NI Technology Updates Outlooks for Diodes Inc, Microsemi, IXYS, International Rectifier and OmniVision Technologies

PRINCETON, N.J., Jan. 5 /PRNewswire/ -- Next Inning Technology Research (http://www.nextinning.com ), an online investment newsletter focused on semiconductor and technology stocks, announced it has updated outlooks for Diodes Inc (Nasdaq: DIOD), Microsemi (Nasdaq: MSCC), IXYS (Nasdaq: IXYS), International Rectifier (NYSE: IRF) and OmniVision Technologies (Nasdaq: OVTI).

Editor Paul McWilliams has displayed uncanny accuracy in predicting the ebb and flow of the markets during the last 12 months. He not only called the relief rally that started in November 2008 and nailed the March bottom to the day, he also predicted the catalysts that would fuel what has been one of the most significant recovery rallies in NASDAQ history.

In his special November Strategy Review, McWilliams called the ups and downs of December with uncanny accuracy and laid out his predictions for 2010. In this extensive report, McWilliams provides an in-depth forecast for a variety of tech sectors, points out what he sees as three danger periods looming in our future, and provides specific investment opinions and price targets on 37 leading tech stocks.

Long-term Next Inning readers know this is an important report. In his special report published in late 2008, he helped position readers early with big winners like Apple, Blue Coat Systems, Diode Inc., Flextronics, 3Com and Sun Microsystems, noting clearly the latter two were acquisition candidates. Prices for these stocks have since advanced between 135% and 250%.

To get the inside scoop on how McWilliams regularly tops broad market performance, investors have the opportunity to take a free 21-day test drive with Next Inning. With this, you'll receive not only McWilliams Strategy Review, but also his highly acclaimed State of Tech reports that will help you position your portfolio for the upcoming January earnings season. With State of Tech you'll get in-depth sector by sector coverage of over 65 leading tech companies and McWilliams specific guidance as to which stocks he thinks you should own and which you should avoid. To take advantage of this offer, please visit the following link:

https://www.nextinning.com/subscribe/index.php?refer=prn940

McWilliams covers these topics and more in his recent reports:

-- In December 2008 McWilliams carefully explained to Next Inning readers why Wall Street was wrong to sell off Diodes Inc. Not only were analysts wrong in their view of the temporary adjustments Diodes was forced to make to its balance sheet, but they were also wrong in how they viewed the aggregate demand for Diodes' products. Based on this view, McWilliams encouraged readers to buy Diode when the stock was trading at only $4.56 with a prediction that they could see returns during the next year approaching 400%. With Diode now up 350% does McWilliams think investors should hold for the full 400% or take some profits? What is McWilliams' fair value price range for Diode?

-- On November 2(nd), McWilliams encouraged Next Inning readers to buy Microsemi at its then current price of $13.31. With the stock now trading above $18, a profit of 37% in only two months, should stock holders take some gains or hold out for more? What is McWilliams fair value price range for Microsemi and what is the basis for his opinion?

-- After suggesting that Next Inning readers buy IXYS last August when the stock was trading in the $6s, McWilliams suggested selling out the position in October at $8.56 for a quick 35% profit. With the price now trending in the mid-$7 range, does McWilliams think it's time to buy back in? What does McWilliams think about IXYS' acquisition of Ledis and its planned acquisition of Zilog? Does McWilliams think IXYS is making a good decision to expand its market strategy through these acquisitions?

-- The price of International Rectifier has nearly doubled since McWilliams listed it as a buy in his special report, "Undervalued Tech Stocks for 2009." What does he see as the risks and the critical success factors investors should monitor going forward? What does he think about the forward earnings consensus for International Rectifier? Does McWilliams think the stock merits holding at its current price?

-- In late 2008, McWilliams suggested that Next Inning readers buy OmniVision at its then current price in the mid-$5s. His reasoning was that the strong balance sheet and a surge in smartphone demand during 2009 would lead to a possible triple. Following this, but months before the news was public, McWilliams advised Next Inning readers that OmniVision had won the coveted image sensor for the new iPhone scheduled for release later that year. When the tear-down reports confirmed the design the price of OmniVision soared. With rumors that the new iPhone due out in 2010 will use an OmniVision sensor and forecasts suggesting sales for the iPhone could double from what they were in 2009, does McWilliams think it will be another good year for OmniVision stockholders?

Founded in September 2002, Next Inning's model portfolio has returned 235% since its inception versus 26% for the S&P 500.

About Next Inning:

Next Inning is a subscription-based investment newsletter that provides regular coverage on more than 150 technology and semiconductor stocks. Subscribers receive intra-day analysis, commentary and recommendations, as well as access to monthly semiconductor sales analysis, regular Special Reports, and the Next Inning model portfolio. Editor Paul McWilliams is a 30+ year semiconductor industry veteran.

NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

CONTACT: Marcia Martin, Next Inning Technology Research, +1-888-278-5515

SOURCE Indie Research Advisors, LLC